RBC Capital analyst Gregory Renza maintained a Hold rating on Iterum Therapeutics (ITRM – Research Report) on November 12 and set a price target of $1.00. The company's shares closed last Monday at $0.46, close to its 52-week low of $0.45. According to TipRanks.com, Renza is a 1-star analyst with an average return of -1.1% and a 30.3% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Verrica Pharmaceuticals, and Inovio Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Iterum Therapeutics with a $1.00 average price target, which is an 110.8% upside from current levels.
https://www.tipranks.com/news/blurbs/iterum-therapeutics-itrm-gets-a-hold-rating-from-rbc-capital-2?utm_source=advfn.com&utm_medium=referral
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Iterum Therapeutics Charts.
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Iterum Therapeutics Charts.